OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
Shun Kohsaka, Carolyn S.P. Lam, Dae Jung Kim, et al.
The Lancet Diabetes & Endocrinology (2020) Vol. 8, Iss. 7, pp. 606-615
Open Access | Times Cited: 78
Shun Kohsaka, Carolyn S.P. Lam, Dae Jung Kim, et al.
The Lancet Diabetes & Endocrinology (2020) Vol. 8, Iss. 7, pp. 606-615
Open Access | Times Cited: 78
Showing 1-25 of 78 citing articles:
Endothelial Dysfunction and Its Clinical Implications
Pavel Poredoš, Aleksandra Visnovic Poredos, Igor D. Gregorič
Angiology (2021) Vol. 72, Iss. 7, pp. 604-615
Closed Access | Times Cited: 106
Pavel Poredoš, Aleksandra Visnovic Poredos, Igor D. Gregorič
Angiology (2021) Vol. 72, Iss. 7, pp. 604-615
Closed Access | Times Cited: 106
Pharmacotherapy of type 2 diabetes: An update and future directions
Antea DeMarsilis, Niyoti Reddy, Chrysoula Boutari, et al.
Metabolism (2022) Vol. 137, pp. 155332-155332
Closed Access | Times Cited: 95
Antea DeMarsilis, Niyoti Reddy, Chrysoula Boutari, et al.
Metabolism (2022) Vol. 137, pp. 155332-155332
Closed Access | Times Cited: 95
Current Trends of Big Data Research Using the Korean National Health Information Database
Mee Kyoung Kim, Kyungdo Han, Seung‐Hwan Lee
Diabetes & Metabolism Journal (2022) Vol. 46, Iss. 4, pp. 552-563
Open Access | Times Cited: 81
Mee Kyoung Kim, Kyungdo Han, Seung‐Hwan Lee
Diabetes & Metabolism Journal (2022) Vol. 46, Iss. 4, pp. 552-563
Open Access | Times Cited: 81
Association of Sodium–Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study
Che‐Yuan Wu, Carina Iskander, Christa Wang, et al.
Diabetes Care (2022) Vol. 46, Iss. 2, pp. 297-304
Open Access | Times Cited: 76
Che‐Yuan Wu, Carina Iskander, Christa Wang, et al.
Diabetes Care (2022) Vol. 46, Iss. 2, pp. 297-304
Open Access | Times Cited: 76
Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
Guntram Schernthaner, Naim Shehadeh, Ametov As, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 127
Guntram Schernthaner, Naim Shehadeh, Ametov As, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 127
Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong
Sharen Lee, Jiandong Zhou, Keith Sai Kit Leung, et al.
Cardiovascular Drugs and Therapy (2022) Vol. 37, Iss. 3, pp. 561-569
Open Access | Times Cited: 42
Sharen Lee, Jiandong Zhou, Keith Sai Kit Leung, et al.
Cardiovascular Drugs and Therapy (2022) Vol. 37, Iss. 3, pp. 561-569
Open Access | Times Cited: 42
Comparison of patient characteristics and in-hospital mortality between patients with COVID-19 in 2020 and those with influenza in 2017–2020: a multicenter, retrospective cohort study in Japan
Yuta Taniguchi, Toshiki Kuno, Jun Komiyama, et al.
The Lancet Regional Health - Western Pacific (2022) Vol. 20, pp. 100365-100365
Open Access | Times Cited: 40
Yuta Taniguchi, Toshiki Kuno, Jun Komiyama, et al.
The Lancet Regional Health - Western Pacific (2022) Vol. 20, pp. 100365-100365
Open Access | Times Cited: 40
Effectiveness and safety of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors in older adults with type 2 diabetes: A nationwide population‐based study
Seung Jin Han, Kyoung Hwa Ha, Nami Lee, et al.
Diabetes Obesity and Metabolism (2020) Vol. 23, Iss. 3, pp. 682-691
Open Access | Times Cited: 68
Seung Jin Han, Kyoung Hwa Ha, Nami Lee, et al.
Diabetes Obesity and Metabolism (2020) Vol. 23, Iss. 3, pp. 682-691
Open Access | Times Cited: 68
Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study
Kåre I. Birkeland, Johan Bodegård, Amitava Banerjee, et al.
Diabetes Obesity and Metabolism (2020) Vol. 23, Iss. 1, pp. 75-85
Open Access | Times Cited: 53
Kåre I. Birkeland, Johan Bodegård, Amitava Banerjee, et al.
Diabetes Obesity and Metabolism (2020) Vol. 23, Iss. 1, pp. 75-85
Open Access | Times Cited: 53
From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes
Ofri Mosenzon, Stefano Del Prato, Meir Schechter, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 51
Ofri Mosenzon, Stefano Del Prato, Meir Schechter, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 51
SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies
Annamaria Mascolo, Cristina Scavone, Lucia Scisciola, et al.
Pharmacological Research (2021) Vol. 172, pp. 105836-105836
Open Access | Times Cited: 46
Annamaria Mascolo, Cristina Scavone, Lucia Scisciola, et al.
Pharmacological Research (2021) Vol. 172, pp. 105836-105836
Open Access | Times Cited: 46
Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
Carolyn S.P. Lam, João Pedro Ferreira, Egon Pfarr, et al.
European Heart Journal (2021) Vol. 42, Iss. 43, pp. 4442-4451
Open Access | Times Cited: 45
Carolyn S.P. Lam, João Pedro Ferreira, Egon Pfarr, et al.
European Heart Journal (2021) Vol. 42, Iss. 43, pp. 4442-4451
Open Access | Times Cited: 45
Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes
Yan Xie, Benjamin Bowe, Andrew K. Gibson, et al.
JAMA Internal Medicine (2021) Vol. 181, Iss. 8, pp. 1043-1043
Open Access | Times Cited: 43
Yan Xie, Benjamin Bowe, Andrew K. Gibson, et al.
JAMA Internal Medicine (2021) Vol. 181, Iss. 8, pp. 1043-1043
Open Access | Times Cited: 43
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Avraham Karasik, Stefanie Lanzinger, Elise Tan, et al.
Diabetes & Metabolism (2023) Vol. 49, Iss. 2, pp. 101418-101418
Open Access | Times Cited: 19
Avraham Karasik, Stefanie Lanzinger, Elise Tan, et al.
Diabetes & Metabolism (2023) Vol. 49, Iss. 2, pp. 101418-101418
Open Access | Times Cited: 19
Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus
Young Sang Lyu, Seok Kyu Oh, Jin Hwa Kim, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 18
Young Sang Lyu, Seok Kyu Oh, Jin Hwa Kim, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 18
Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease
Karn Wijarnpreecha, Elizabeth S. Aby, Aijaz Ahmed, et al.
Clinical and Molecular Hepatology (2020) Vol. 27, Iss. 2, pp. 221-235
Open Access | Times Cited: 42
Karn Wijarnpreecha, Elizabeth S. Aby, Aijaz Ahmed, et al.
Clinical and Molecular Hepatology (2020) Vol. 27, Iss. 2, pp. 221-235
Open Access | Times Cited: 42
Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review
Thahesh Tharmaraja, Jamie Sin Ying Ho, Ching‐Hui Sia, et al.
Therapeutic Advances in Chronic Disease (2022) Vol. 13, pp. 204062232210869-204062232210869
Open Access | Times Cited: 24
Thahesh Tharmaraja, Jamie Sin Ying Ho, Ching‐Hui Sia, et al.
Therapeutic Advances in Chronic Disease (2022) Vol. 13, pp. 204062232210869-204062232210869
Open Access | Times Cited: 24
SGLT inhibitors for improving Healthspan and lifespan
James H. O’Keefe, Robert Weidling, Evan L. O’Keefe, et al.
Progress in Cardiovascular Diseases (2023) Vol. 81, pp. 2-9
Open Access | Times Cited: 15
James H. O’Keefe, Robert Weidling, Evan L. O’Keefe, et al.
Progress in Cardiovascular Diseases (2023) Vol. 81, pp. 2-9
Open Access | Times Cited: 15
Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome
Hiroki Akiyama, Akihiro Nishimura, Naru Morita, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 14
Hiroki Akiyama, Akihiro Nishimura, Naru Morita, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 14
Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches
Jing Xu, Taro Hirai, Daisuke Koya, et al.
Journal of Clinical Medicine (2021) Vol. 11, Iss. 1, pp. 137-137
Open Access | Times Cited: 32
Jing Xu, Taro Hirai, Daisuke Koya, et al.
Journal of Clinical Medicine (2021) Vol. 11, Iss. 1, pp. 137-137
Open Access | Times Cited: 32
SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism
Xiaodan Wang, Jingyu Ni, Rui Guo, et al.
Heart Failure Reviews (2021) Vol. 27, Iss. 3, pp. 961-980
Closed Access | Times Cited: 31
Xiaodan Wang, Jingyu Ni, Rui Guo, et al.
Heart Failure Reviews (2021) Vol. 27, Iss. 3, pp. 961-980
Closed Access | Times Cited: 31
Cardiovascular Effectiveness of Sodium‐Glucose Cotransporter 2 Inhibitors and Glucagon‐Like Peptide‐1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure
Phyo T. Htoo, John B. Buse, Matthew A. Cavender, et al.
Journal of the American Heart Association (2022) Vol. 11, Iss. 4
Open Access | Times Cited: 19
Phyo T. Htoo, John B. Buse, Matthew A. Cavender, et al.
Journal of the American Heart Association (2022) Vol. 11, Iss. 4
Open Access | Times Cited: 19
Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta‐analysis
Hongwei Cao, Tao Liu, Li Wang, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 8, pp. 1448-1457
Open Access | Times Cited: 19
Hongwei Cao, Tao Liu, Li Wang, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 8, pp. 1448-1457
Open Access | Times Cited: 19
Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes
André Scheen
Diabetes & Metabolism (2021) Vol. 47, Iss. 6, pp. 101275-101275
Closed Access | Times Cited: 26
André Scheen
Diabetes & Metabolism (2021) Vol. 47, Iss. 6, pp. 101275-101275
Closed Access | Times Cited: 26
Lower risk of hospitalization for heart failure, kidney disease and death with sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care
Iskandar Idris, Ruiqi Zhang, Jil Billy Mamza, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 10, pp. 2207-2214
Open Access | Times Cited: 25
Iskandar Idris, Ruiqi Zhang, Jil Billy Mamza, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 10, pp. 2207-2214
Open Access | Times Cited: 25
